Skip to content

EV / sales at other companies

Mirum Pharmaceuticals, Inc. logo
Mirum Pharmaceuticals, Inc.MIRM
9.4×+4.0×
Arrowhead Research logo
Arrowhead ResearchARWR
14×+10.9×
Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
12.2×+5.7×
BridgeBio Pharma logo
BridgeBio PharmaBBIO
28.9×-18.5×
TG Therapeutics logo
TG TherapeuticsTGTX
-8.3×
Alkermes logo
AlkermesALKS
4.6×+1.2×

Other financials

Income statement

See full
Revenue$132.9M+4,158%
Gross profit$1.6M+6.5%
Operating income$61.5M+274%
Net income$52.9M+238%
EPS (diluted)$0.52+216%

Balance sheet

See full
Cash & equivalents$222.8M+31.2%
Total debt$7.0M+1.5%
Total equity$108.6M+118%
Total assets$401.5M+76.6%

Cash flow

See full
Operating cash flow$53.0M+273%
CapEx$2.8M+758%
Free cash flow$50.2M+262%

Valuation

See full
Market cap$6.32B+164%
Enterprise value$6.1B+184%
P/S21.9×-147×

Profitability

See full
Gross margin58.1%-18.7pp
Operating margin-155%-68.1pp
Net margin-176.2%-76.4pp
FCF margin-150.7%-64.4pp

Returns & leverage

See full
Return on equity-181%+57.4pp
Debt / equity0.1×-0.1×
Current ratio2.2×-0.7×

Where this comes from

Calculated from Liquidia Corporation’s reported figures.

Based on the most recent quarter.

The official record: Liquidia Corporation’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Liquidia Corporation's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Liquidia Corporation's EV / sales?
Liquidia Corporation (LQDA) reported EV / sales of 10.8× in Q1 2026.
How has Liquidia Corporation's EV / sales changed year-over-year?
Liquidia Corporation's EV / sales decreased by 86.1% year-over-year, from 77.4× to 10.8×.
What is the long-term trend for Liquidia Corporation's EV / sales?
Over 4 years (2020 to 2024), Liquidia Corporation's EV / sales has grown at a -19.7% compound annual growth rate (CAGR), from 142.2× to 59×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.